Adrian Hayday

This inventor holds 17 USPTO granted patents and 11 published patent applications, plus 8 CIPO patents and 13 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Immunoqure Ag, King's College London, Gammadelta Therapeutics Ltd. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adrian Hayday. Retrieved from https://idiyas.com/inventor/adrian-hayday

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 11)

% Patents Active = 82.4

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 23)

Average Co-Inventor Count = 6.3

ph-index = 4

Forward Citations = 24(Granted Patents)

Location History:

Orpington, GB (2018 - 2021)
Kent, GB (2016 - 2023)
Orpington Kent, GB (2024)

Company Filing History:

King's College London

patents

3 out of 8

Gammadelta Therapeutics Ltd

patents

4. 2 out of 269

Cancer Research Technology Limited

patents

5. 2 out of 11

The Francis Crick Institute Limited

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Gamma Delta T Cells

Immunotherapy

Nucleic Acid Molecules

Activated Monocytes

Antibody Constructs

Human Antibodies

IL-17F

IL-22

IFN-α

IL-32

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698328 - NOVEL ANTIBODIES (2026-08-04),

2. 12637659 - Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells (2026-05-26),

3. 12458698 - Expansion of γδ T cells, compositions, and methods of use thereof (2025-11-04),

4. 12364755 - Method for obtaining globally activated monocytes (2025-07-22),

5. 12152064 - BTNL3/8 targeting constructs for delivery of payloads (2024-11-26),

6. 11945861 - Human anti-IFN-α antibodies (2024-04-02),

7. 11655453 - Expansion of γδ T cells, compositions, and methods of use thereof (2023-05-23),

8. 11618885 - Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells (2023-04-04),

9. 11179417 - Method for obtaining globally activated monocytes (2021-11-23),

10. 10975144 - CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody (2021-04-13),

11. 10941198 - Human anti-IFN-α antibodies (2021-03-09),

12. 10875916 - Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F (2020-12-29),

13. 10131709 - Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 (2018-11-20),

14. 10112995 - Human anti-IFN-α antibodies (2018-10-30),

15. 10081676 - Human anti-IL-32 antibodies and methods of making and using the same (2018-09-25),

Title: Exploring the Innovations of Inventor Adrian Hayday

Introduction

Adrian Hayday is a prominent inventor based in Kent, Great Britain, known for his significant contributions to the field of medical research and immunology. With a remarkable portfolio of 12 patents, Hayday has developed groundbreaking innovations that enhance our understanding and treatment of various diseases.

Latest Patents

One of Adrian Hayday's latest patents involves the development of human anti-IFN-α antibodies. This invention provides novel IFN-α binding molecules of human origin, notably human-derived anti-IFN-α antibodies, along with their binding fragments, derivatives, and variants. The patent also outlines pharmaceutical compositions, kits, and methodologies for diagnosis and therapy applications.

Another significant patent from Hayday focuses on the expansion of γδ T cells, outlining innovative methods to expand these cells from non-haematopoietic tissue sources. The patent further includes compositions of the expanded γδ T cells and their applications in adoptive T cell therapy, showcasing Hayday's commitment to advancing therapeutic techniques in immunology.

Career Highlights

Adrian Hayday has built a reputable career while working at esteemed institutions such as Immunoqure Ag and King's College London. His experiences at these organizations have significantly contributed to his innovative research and the development of his patented technologies.

Collaborations

Throughout his career, Hayday has collaborated with notable individuals in the field, including his coworkers Kai Krohn and Kai Kisand. These partnerships have likely fostered a productive exchange of ideas and practices that have advanced their collective work in immunology and therapeutic development.

Conclusion

Adrian Hayday's contributions to science and medicine are marked by his innovative spirit and relentless pursuit of knowledge. His patents not only reflect his dedication to research but also pave the way for new therapeutic avenues, greatly impacting the landscape of medical science. As innovation continues to evolve, the work of inventors like Hayday remains crucial in shaping a healthier future.

Profile summary based on public USPTO records.